"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).
| Descriptor ID |
D019139
|
| MeSH Number(s) |
G12.900
|
| Concept/Terms |
Tumor Escape- Tumor Escape
- Tumor Immune Evasion
- Evasion, Tumor Immune
- Evasions, Tumor Immune
- Immune Evasions, Tumor
- Tumor Immune Evasions
- Immune Evasion, Tumor
- Immune Escape, Tumor
- Tumor Immune Escape
|
Below are MeSH descriptors whose meaning is more general than "Tumor Escape".
Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".
This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 7 | 9 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 3 | 3 |
| 2013 | 2 | 5 | 7 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 3 | 5 |
| 2016 | 5 | 4 | 9 |
| 2017 | 1 | 4 | 5 |
| 2018 | 5 | 3 | 8 |
| 2019 | 8 | 4 | 12 |
| 2020 | 7 | 5 | 12 |
| 2021 | 9 | 3 | 12 |
| 2022 | 0 | 3 | 3 |
| 2023 | 2 | 1 | 3 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Escape" by people in Profiles.
-
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024 Oct; 26(10):1773-1789.
-
T cell dysfunction and therapeutic intervention in cancer. Nat Immunol. 2024 Aug; 25(8):1344-1354.
-
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Oncoimmunology. 2024; 13(1):2376264.
-
Pan-cancer proteogenomics characterization of tumor immunity. Cell. 2024 Feb 29; 187(5):1255-1277.e27.
-
The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy. Front Immunol. 2023; 14:1237715.
-
Uncovering the IL-1?-PCAF-NNT axis: A new player in ferroptosis and tumor immune evasion. Cancer Commun (Lond). 2023 09; 43(9):1048-1050.
-
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023 02 01; 133(3).
-
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022 Oct; 28(10):2133-2144.
-
Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. Cell Mol Immunol. 2022 10; 19(10):1153-1167.
-
Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022 04; 22(4):195-207.